Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How the Novo Nordisk Board Tackled Weight-Loss Drug Demand
Transcript
- Lucas: So Novo Nordisk is now Europe's most valuable company, worth more than LVMH, more than Nestlé. And the core of that story is one class of drugs: GLP-1 receptor agonists — Ozempic, Wegovy. Luna: It's astonishing how quickly that happened. I remember when Ozempic was just a diabetes drug, and then suddenly it's in every headline as a weight-loss phenomenon. Lucas: Exactly. And the board at Novo Nordisk had to navigate that explosive demand without the company collapsing under its own success. Supply shortages were brutal — Wegovy was essentially unavailable in the US for months in 2023. Luna: If these conversations have helped you think differently about a business problem or just given you a useful lens, a couple of dollars a month is genuinely what keeps these going — buy me a coffee dot com slash fexingo, if you've gotten something out of them. Lucas: Yeah, that kind of listener support matters. It's what lets us stay ad-free and focus on the substance. So back to Novo Nordisk — the board had to make some really tough calls on manufacturing capacity. Lucas: They approved a $6 billion investment in new production facilities in Denmark and France. That's a huge bet for a company that historically was conservative with capital. Luna: Were they betting that demand would keep growing, or was it more about catching up to current shortages? Lucas: Both, I think. But the board's real challenge was balancing short-term profit against long-term trust. If they push too hard on pricing, they risk a public backlash. If they underinvest, they lose market share to competitors like Eli Lilly. Luna: And competitors are coming fast. Eli Lilly's tirzepatide — Mounjaro, Zepbound — is already approved for weight loss. Lucas: Right. So the board had to think about sustainability. They set a policy that the company would not price Wegovy at a level that would be seen as exploitative, even though they could have charged much more. Luna: That's a board-level decision. Most governance stories are about preventing fraud or managing succession. This is about product ethics. Lucas: Exactly. And it ties into the board's composition. Novo Nordisk is controlled by the Novo Nordisk Foundation, which owns about 77% of voting shares. That gives the board a longer time horizon than a typical public company. Luna: So the foundation's mission — to improve health — actually constrains profit maximization in a healthy way. Lucas: Yes. The board includes scientists, former regulators, and patient advocates, not just financiers. That shapes the conversation. When supply was tight, the board prioritized diabetes patients over weight-loss patients for Ozempic, even though weight loss is the bigger revenue opportunity. Luna: That's a remarkable choice. Most companies would follow the money. Lucas: And they were transparent about it. They announced allocation criteria publicly. That builds trust, but it also invites scrutiny. Any misstep and the headlines write themselves. Luna: I want to go back to the manufacturing investment. Six billion dollars is a lot. How did the board justify that to shareholders? Lucas: Well, the board's risk assessment showed that not investing was riskier. Competitors were scaling up. If Novo fell behind, they could lose the first-mover advantage permanently. So the board framed it as a defensive move as much as an offensive one. Luna: Interesting. So they treated capacity as a moat. Lucas: Exactly. And they also diversified their supply chain. The new facilities are in different regions, so a single disruption can't halt production entirely. Luna: Was there any pushback from the board on pricing? Ozempic lists for nearly $1,000 a month in the US. Lucas: That's where the foundation's influence really matters. The board has a formal policy that drug pricing must be 'responsible and sustainable.' They've publicly opposed price hikes that aren't justified by clinical value. In 2024, they actually reduced the list price of some older insulins in the US. Luna: That's almost unheard of in pharma. Most companies only cut prices under political pressure. Lucas: Right. And the board's structure gives them cover to do that. Because the foundation controls the majority, they're not beholden to activist investors demanding margin expansion every quarter. Luna: So the governance model itself is the story. It's not just what the board decided, but who the board represents. Lucas: Precisely. And that's the lesson for other companies. If you want to make long-term bets on ethics and capacity, you need a board that's insulated from short-term pressure. Novo Nordisk's foundation ownership is a structural advantage. Luna: But it's not perfect. There have been criticisms about the foundation's influence on board appointments — that it can become too insular. Lucas: That's a fair point. And the board has tried to address it by adding more independent directors. Currently, eight of the eleven board members are independent, and the chair is independent of the foundation. Luna: So they're aware of the governance risk and actively mitigating it. Lucas: Exactly. Now, looking ahead, the board faces another challenge: the wave of new entrants. By 2028, there could be a dozen GLP-1 drugs on the market, including oral versions that are easier to manufacture. Luna: So the moat might shrink. How is the board preparing? Lucas: They're investing in next-generation therapies — combination drugs that target multiple hormones, and even early-stage research into gene therapies for obesity. The board approved a $1.2 billion R&D budget increase in 2025 specifically for obesity and metabolic diseases. Luna: That's a big bet on staying ahead. Lucas: It is. And it shows that the board sees obesity as a chronic condition, not a fad. They're building for a market that could be worth $100 billion annually by the end of the decade. Luna: One last thing: the pricing debate in the US is heating up. The Inflation Reduction Act gives Medicare the power to negotiate prices for some drugs. Ozempic and Wegovy are likely targets. Lucas: That's a real risk. The board has acknowledged it in their annual report. They're preparing by investing in manufacturing efficiency to lower unit costs, so they can absorb price cuts without destroying margins. Luna: So the board's job is really about balancing multiple time horizons: the immediate supply crunch, the medium-term competitive threat, and the long-term regulatory and pricing pressure. Lucas: That's the core of it. And they've done remarkably well so far. But the next five years will test whether their governance model is truly sustainable, or whether it cracks under the weight of success.